Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina

BACKGROUND: Sacubitril/valsartan (an Angiotensin receptor-neprilysin inhibitor—ARNI) is one of the cornerstones in the management of patients with heart failure with reduced ejection fraction (HFrEF) having demonstrated significant reductions in both mortality and hospitalisations as compared with e...

Descripción completa

Detalles Bibliográficos
Autores principales: Giorgi, Mariano A., Boissonnet, Carlos P., Luque, Paula Soledad, Piastrella, Jimena, Porley, Carlos, Ditata, Fernanda, Volman, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938575/
https://www.ncbi.nlm.nih.gov/pubmed/36808581
http://dx.doi.org/10.1186/s13561-023-00427-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938575/
https://www.ncbi.nlm.nih.gov/pubmed/36808581
http://dx.doi.org/10.1186/s13561-023-00427-w

Ejemplares similares